Ingelheim, Germany, 5 April 2017 – The research-driven pharmaceutical company Boehringer Ingelheim can look back on a successful financial year. Net sales increased in all businesses. At the same time, Boehringer Ingelheim completed the transformation of the company as planned in 2016, and will in future focus on human pharmaceuticals, animal health and biopharmaceutical contract manufacturing. “Both our human pharmaceuticals as well as our animal health medications contributed to our positive business performance with good growth rates,” explained Hubertus von Baumbach, Chairman of the Board of Managing Directors, at the annual press conference today. “We look to the future with confidence – especially after successfully completing the transformation of our business.” [Click on the card to read more...]